ABSTRACT
C-erbB2 is over-expressed or amplified in many carcinomas. We assessed the relationship between erb-B2 immunoreactivity, and its predictive role in progressionfree survival and treatment outcome in patients with cervical carcinoma. Sections from 65 cervical carcinoma were immunostained with antiboty to p185 erbB2. Immunoreactive ErbB2 was found in 25 patients (38%) [+ 15 pts. (23%); ++ 10 pts. (15%)]. There were no correlation with age, performance status, grading and histology. Erb-B2 immunoreactivity significantly correlated with stage of the disease. Positive immunoreacivity was found in 63%, 44%, 14% and 0% of stage I, II, III and IV carcinomas, (p = 0.0045). Progression-free survival was longer in erb-B2 positive patients without reaching significance. No correlation was found between erbB2 and response to radiotherapy or chemotherapy. In conclusion, a significant proportion of stage I and II cervical cancer express erb-B2 compared to more advanced stages. Expression of the oncogene does not appear to be related to prognosis or treatment outcome.
INTRODUCTION
Despite the introduction of the PAP smear screening technique, cervical carcinoma is still one of the leading cause of cancer death in women worldwide. Cervical cancers develop from precursor lesions, which are termed squamous intraepithelial lesions and are graded as high or low, depending on the degree of disruption of epithelial differentiation. The involvement of human papillomavirus (HVP) subtypes 16, 18, 31, 33 and 51 in the development of cervical carcinoma has been firmly established (1). However, other genetic alterations, such as abnormal expression of oncoproteins, may play an important role in the pathogenesis of this tumor and may offer potential targets for biological therapy. Several oncogenes have been evaluated as prognostic biomarkers in cervical cancer, including c-myc (2, 3), c-erbB2 (4-6), Ki-67 (7, 8) , nm23-H1(9) and metalloproteinase (10) . However, the reported results are sometimes conflicting and no single marker has proved to be a significant prognostic indicator. The c-erbB2 gene codes for a transmembrane, 185 kD tyrosine kinase receptor protein closely related to epidermal growth factor receptor, the cerbB2 oncoprotein, also called HER-2/neu (11) . The abnormal expression of c-erbB2 has recently become clinically important in oncology since in breast cancer with c-erbB2 amplification the addition of trastuzumab, a humanized monoclonal anti-c-erbB2 antibody, to standard chemotherapy yields significantly higher response rate and longer survival (12) .
Although point mutations in the transmembrane or noncatalytic sequences have been reported, the most frequent activating alterations of c-erbB2 involved in the pathogenesis of human cancer is gene amplification and oncoprotein overexpression (13) . In 15-30% of the breast cancers c-erbB2 is amplified and overexpressed, which is associated with aggressive tumor behavior and shortened overall survival (14) . The prognostic role of c-erbB2 in cervical carcinoma remains controversial: in several studies c-erbB2 overexpression and/or amplification has been associated with poor clinical outcome (5, (15) (16) (17) , whereas others have shown no prognostic effect (6, 18, 19) or even a positive effect on survival (4) . Difficulties in interpreting and comparing the results of these studies may depend on differences in antibodies and protocols used to analyze the expression of c-erbB2 oncoprotein and on the small number of patients studied. The aim of this study was to evaluate the relationship between c-erbB2 immunohistochemical staining and main baseline characteristics of patients diagnosed with cervical carcinoma and to determine the prognostic role of c-erbB2 expression on progression-free survival and treatment outcome.
METHODS
Sixty-five patients with uterine cervical carcinoma treated at the National Cancer Institute of Naples were included in this study. Paraffin sections prepared from the 65 cervical cancers were immunostained with antip185 erbB2 (CB11 monoclonal, Novocastra Laboratories, Newcastle upon Tyne, UK). Streptavidin-biotin immunohistochemistry was performed on 4 m sections from paraffin-embedded tissue. Sections were deparaffinizzed, cleared and antigens were retrieved by microwave irradiation. Slides were treated with a 3% solution of hydrogen peroxidase in methanol to block the endogenous peroxidase activity and then washed in PBS before immunoperoxidase staining. After incubation with the primary Ab (1:50 in PBS) at 4°C overnight, tissue sections were covered with biotinylated anti-mouse immunoglobulins, followed by peroxidase labelled streptavidine; the signal was developed by using DAB chromogen as substrate. After chromogen development, slides were washed, dehydrated with alcohol and xilene, and mounted with cover slips using a permanent mounting medium. C-erbB-2/HER2 positive staining was observed in cancer membrane. The intensity was considered strong (++) if detectable in >50% of cells and weak (+) if detectable in <50% of cells.
Statistical methods
Correlations among main patient or tumor characteristics (ECOG performance status, stage, grading, histotype) and c-erbB2 immunohistochemical staining were described by contingency tables and analyzed by chi square test. Difference of age distribution between c-erbB2 negative and c-erbB2 positive cases was analyzed by the Kruskal-Wallis test. Objective response to first treatment received by the patients (chemotherapy or radiotherapy) was classified in three categories: complete response, partial response and no response (stable disease, progressive disease or not evaluated). Progression-free survival (PFS) was defined as the interval from date of baseline visit to date of progression or death whichever occurred first or last follow-up information for patients alive and progression-free. In order to analyze the impact of c-erbB2 expression on PFS, survival curves were drawn with the Kaplan-Meier product limit method [20] and compared with the Mantel-Haenszel test [21] . Relative hazard of progression and death with 95% confidence intervals (CI) were estimated by using the Cox proportional hazards model [22] , considering stage (increasing) as a covariate. All statistical tests were two-tailed and P values less than 0.05 were considered statistically significant. Analyses were performed with S-PLUS software (S-PLUS 6.0 Professional, release 1; Insightful Corporation, Seattle, WA, USA).
RESULTS

Patients
All sixty-five patients were considered for the analysis. The main characteristics of the patients are reported in table 1. The median age of the patients was 51 years (range 29-89). Most of the patients, at the baseline evaluation, had a good Performance Status (0 or 1 in 97% of the patients). An early stage of the disease was present in the majority of the patients (29% stage I, 38% stage II). Most patients were affected by the squamous histotype (95%), with grading 3 in 69 % of the cases. Initial treatment was surgery in 26 cases (41%), neoadjuvant chemotherapy in 20 patients (31%), and definitive radiotherapy in the remaining 18 cases (28%).
Association of erb-B2 expression with patients'characteristics
As shown in table 2 the p185 erbB2 staining was positive in 25 patients (38%) [1+ #15 (23%); 2++ #10 (15%)]. There was no significant correlation with age, performance status, grading and histology. Figure 1 shows that Erb-B2 immunostaining was significantly associated with stage of disease. It was positive in 63%, 44%, 14% and 0% of stage I, II, III and IV, respectively (p = 0.0045). Table 3 shows the response rate to chemotherapy and radiotherapy treatment and Erb-B2 expression. All patients received a platinum-based combination chemotherapy. No significant correlation was found between erbB2 staining and response to chemotherapy in the 20 patients that underwent chemotherapy as neoadjuvant treatment (complete response, partial response and no response were observed in 20%, 47% and 33% versus 20%, 60% and 20% in the 15 ErbB2 negative and in the 5 positive patients, respectively). Again, no significant correlation was found between erbB2 staining and response in the 18 patients treated with definitive radiotherapy (complete response, partial response and no response were observed in 73%, 20% and 7% versus 67%, 33% and 0% in the 15 ErbB2 negative and in the 3 positive patients, respectively). Progression-free survival was longer for patients with erb-B2 positive compared with erb-B2 negative immunostaining (median TTP 51.9 vs NA; 1-year 79.5% vs 83.5%; 2-year 63.6% vs 73.2%), without reaching significance (p=0.142). However, at multivariate analysis considering c-erbB2 expression and stage (reported in table 4), only stage was a significant predictor of progression-free survival.
Association of Erb-B2 immunostaining with treatment outcomes
DISCUSSION
In this study we found that a significant proportion of cervical cancer express erb-B2. Immunostaining was more frequently associated with early stage of disease while no correlation was found with treatment outcome.
Despite advances in early diagnosis and treatment, cervical cancer remains a leading cause of cancer death worldwide. In locally advanced stages, neoadyuvant chemotherapy and surgery or radioterapy and concurrent chemotherapy are considered the therapy of choice and trials are ongoing to compare these strategies. Though a complete response to treatment is achieved in most patients about 50 % of the cases recur and ultimately die of the disease. Thus, new therapeutic options are needed and the inclusion of drugs acting on biological targets to standard radio and chemotherapy seems promising. In breast cancer, trastuzumab, a humanized monoclonal anti c-erb-B2 was shown to potentiate the effectivenes of chemotherapy and some attempts have been done also in gynecologic malignancies (23) .
Overexpression of erb-B2 has been reported in several cancer types including cervical cancer. However, the reported detection rate of erb-B2 in primary cervical cancer varies greatly in the literature (5, 16, (24) (25) (26) (27) . In fact, erb-B2 expression assayed by immunohistochemistry has ranged from 9 to 42 % of the cases (16-19, 24, 28) .
In this study we assessed c-erb-B2 expression in 65 consecutive patients treated for cervical cancer in our institution. We found no correlation of erb-B2 immunostaining and patient age, histology (squamous vs adenocarcinoma) and grading. On the contrary, we observed that the expression of c-erb-B2 was more frequent in stage I and II than in more advanced stages with only 14 % of stage III and no patient with stage IV expressing erb-B2 compared with 63% and 44 % of stage I and II, respectively. Our data are partially in disagreement with those reported by Kersemaekers et al (28) that found a more frequent expression of c-erb-B2 in stage II and III compared to stage I. However, other authors have found that overexpression is frequently present in cervical intraepithelial neoplasia (CIN III), thus suggesting that p185 c-erb-B2 is expressed early during carcinogenesis (29). Since we found that c-erb-B2 expression is inversely correlated to stage, it is possible to hypothesize that the different detection rate reported in previous studies may depend on the relatively small number of patients analyzed with a different relative proportion of early compared to more advanced stages of disease (16-19, 24, 28) .
In the present study we also evaluated if erb-B2 overexpression was correlated to treatment outcome and to response to chemotherapy or radiotherapy. Literature data on the prognostic role of erb-B2 expression in cervical cancer are controversial with some studies with small series of patients suggesting an unfavourabls prognostic role for erb-B2 overexpression. Wook Kim and colleagues (30) reported more than ten years ago that overexpression of erb-B2 is associated to a lower response rate to neoadjuvant chemotherapy in cervical cancer, but these data have never been confirmed.
In our patients no difference was found in progression free survival between erb-B2 negative and positive patients at immunostaining. We also found in the 20 patients treated with chemotherapy and in the 18 treated by radiotherapy that there was no difference in response rate between the two groups. To our knowledge this is the largest series evaluating the effect of erb-B2 overexpression on treatment outcome. Although the numbers does not allow to reach a definitive conclusion it seems that erb-B2 does not modify the response to chemotherapy and radiotherapy in cervical cancer.
In conclusion in this study we showed that a significant proportion of stage I and II cervical cancer express erb-B2. Expression of the oncogene does not appear to be related to prognosis and treatment outcome although further investigation is needed.. 
